ArticleCureus2026
An Adult Case of Chest Wall Langerhans Cell Histiocytosis Mimicking Malignancy and Responding to Targeted Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Langerhans cell histiocytosis (LCH) is a rare clonal proliferation of dendritic cells that is exceptionally uncommon in adults and only rarely affects the chest wall. Adult rib lesions often radiographically mimic malignancy, necessitating biopsy for accurate diagnosis. We report the case of a 52-year-old woman with Class III (severe) obesity and newly diagnosed type 2 diabetes who developed a painful right chest wall mass following severe coughing during coronavirus disease 2019 (COVID-19). Imaging revealed a lobulated lesion with rib erosion and pleural indentation concerning for malignancy. Surgical debridement yielded histiocytic inflammation, and cultures grew Staphylococcus epidermidis. Final histopathology confirmed LCH. Despite wound re-closures and antibiotic therapy, persistent drainage continued until molecular testing identified a B-Raf proto-oncogene, serine/threonine-protein kinase (BRAF) V600E mutation. Targeted therapy with dabrafenib and trametinib was initiated, resulting in rapid clinical improvement and complete wound healing. Adult chest wall LCH represents a rare diagnostic challenge due to its malignant radiographic appearance. Histopathologic confirmation, with molecular testing, is essential, and targeted BRAF/mitogen-activated protein kinase kinase (MEK) inhibition may provide an effective therapeutic option when conventional measures fail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.